Evaluating the utilisation of Climate-Smart Agriculture (CSA) technologies and practices among smallholder farmers in The Lawra, Jirapa and Nandom districts of Ghana

Climate change is posing threat to agriculture in sub-Saharan Africa including Ghana. Climate-Smart Agriculture (CSA) is proposed to solve climate change impacts on agriculture. Smallholder farmers are adopting various strategies to be resilient to climate change effects. Empirical research is required to evaluate CSA utilisation in Ghana. Lawra, Jirapa and Nandom districts in the climate-risk areas of Guinea Savannah agro-ecological zone were chosen and Participatory Rapid Appraisal (PRA) tools were used. Farm budget analysis and market price methods were employed; key financial decision-making tools were net returns, profit margins and benefit-cost ratio. Soft systems content analysis, frequencies, means, ranking and data aggregation were employed to generate results. CSA use in the study districts was smallholder driven and male dominated. CSA was mainly used for staples including cereals and legumes and small ruminants under livestock. Crop-livestock integration and crop rotation were the common CSA practices with the highest costs (GH¢6,370.00) and highest revenues (GH¢9,460.00) respectively. Utilisation of CSA in the districts is beneficial and investments are profitable and financially viable. All actors and stakeholders must join forces to promote CSA in the districts. Rigorous promotional campaigns, capacity building and funding at all levels are crucial for CSA adoption in Ghana

Effects of replacing fishmeal with black soldier fly larval meal in the diets of grower-finishing guinea fowls reared under tropical conditions

The study was conducted with the view to determine the impact of replacing fishmeal with black soldier fly larval meal (BSFLM) on growing guinea fowls. BSFLM replaced fishmeal (3% in the control diet) in the ratios of 0, 20, 40, 60, 80, and 100% to produce six dietary treatments, which were iso-caloric and iso-nitrogenous. Two hundred and forty-eight-week old guinea fowls with mean live weight of 273.2 ± 10.9 g were tagged, weighted, and randomly assigned to 24 (6 × 4) floor pens; each pen was treated as a replicate. Feed and water were provided ad libitum during the entire period, which lasted 10 weeks. Feed consumption differed among the treatment groups (P = 0.0072) with the 100% fishmeal diets recording the lowest. Daily gain was significantly (P = 0.009) higher for birds fed high BSFLM diets compared to the control (100% fishmeal diet). The inclusion of BSFLM in the diets elicited positive linear effect on weight gains of the guinea fowls (R2 = 0.91) with increasing concentration resulting in higher live weight gains. The feed conversion ratio (FCR) also differed between treatments (P < 0.05) but similar for the 100% fishmeal (control) and 100% BSFLM diets. Organ and haematopoitic integrity were equally assured regardless of levels of the protein sources fed to the birds. Generally, meats from birds fed 60 to 100% BSFLM and from hens were more acceptable. A study to evaluate the economics of utilising BSFLM in guinea fowl production is recommended

Science-policy interactions for climate-smart agriculture uptake: lessons learnt from national science-policy dialogue platforms in West Africa

Science–policy interfaces are critical in shaping agricultural and environmental governance. However, connecting science with policy has always been a challenge for both scientists and policymakers. In Ghana, Mali and Senegal, the CGIAR Research Program on Climate Change, Agriculture and Food Security (CCAFS) supported the creation of a multi-stakeholder national science-policy dialogue platforms on climate-smart agriculture (NSPDP-CSA) to use scientific evidence to create awareness on climate change impacts on agriculture and advocate for the mainstreaming of climate change and climate-smart agriculture (CSA) into agricultural development plans. Since their establishment, there is limited information as to how the modes of operation and achievements of the NSPDP-CSA improve our understanding of the sciencepolicy interfaces of agricultural and climate change decision making. This study aimed to use the evidence from the operations and achievements of the NSPDP-CSA to make recommendations for effective science-policy interaction on climate change and CSA. We used semi-structured questionnaire interviews and review of technical reports produced by the platforms to obtaining the information aforementioned. The results showed that using NSPDPCSA may be an innovative approach to effectively engaging policymakers/decision-makers for climate change and CSA mainstreaming into agricultural development policies and plans in Ghana, Mali and Senegal. For effective science-policy interaction, the study suggests the following recommendations: (a) Institutionalising the NSPDP-CSA through embedding them within national institutions improves their credibility, relevance and legitimacy among policymakers; (b) two-way communication may have a phenomenal advantage in the codevelopment of solutions that address climate change vulnerabilities and impacts; and (c) using relevant communication products and packaging CSA and climate change with evidence to align with country priorities will facilitate readily uptake in policy decision-makings. A framework of operation for the platforms was suggested based on lessons learnt from the 3 countries’ experiences and achievements

Capacitating Science-Policy dialogue platforms to trigger actions for accessing climate finance: experiences and lessons learnt from Ghana, Mali and Niger

Adequate financial resources are key barriers limiting the effectiveness and sustainability of the national science-policy dialogue platforms in West Africa. This Info Note documents the outcomes of and lessons learnt from capacity building activities to science-policy dialogue platforms in Ghana, Mali and Niger and how the capacity building program empowered the platforms and/or triggered actions for accessing climate finance. A structured engagement and capacity building approach was implemented to strength resource mobilization capacity of the science-policy dialogue platforms in Ghana, Mali and Niger. The approach has enabled the development of three GCF concept notes and two bilateral donor proposals for accessing climate finance. The structured engagement and capacity building approach adopted was instrumental in triggering actions. The strong commitment and leadership of the institutions hosting the secretariat of the platforms were also crucial in triggering action

Implementation, usage, and effectiveness of Ghana climate change policies: an assessment of the national CSA Action Plan and CSA Investment Framework

" Five years after the adoption of CSA Action Plan, followed by a CSA Investment Framework, it was crucial to assess the level of implementation and usage and draw lessons on the effectiveness of these two policy documents. This study aims to provide a scientific-based assessment of the level of implementation, usage, and effectiveness of the above-mentioned two Ghana climate change policy documents. Due to low awareness of stakeholders, the implementation of the CSA Action Plan and CSA Investment Framework is low (19% of studied districts). The usage of the CSA Action Plan focuses more on crop value chain development followed by livestock and fish value chains. The CSA Investment Framework was used to mobilize resource to develop climate-resilient cropping systems, alternative livelihood systems, post-harvest management, market systems, and water conservation activities. The effectiveness of the CSA Action Plan and CSA Investment Framework depends on the number of target beneficiaries, budget allocation and funds mobilized. Multipurpose policy instruments are critical for bringing about a conducive environment to address climate change and related risks. Increasing awareness of the CSA Action Plan is a key pathway to enhance its usage, implementation and effectiveness across scales. To enable effective use of the CSA Investment Framework, there is a need to enhance the capacity of key stakeholders on the development of bankable proposal

Constructing “Packages” of Evidence-Based Programs to Prevent Youth Violence: Processes and Illustrative Examples From the CDC’s Youth Violence Prevention Centers

This paper describes the strategic efforts of six National Centers of Excellence in Youth Violence Prevention (YVPC), funded by the U.S. Centers for Disease Control and Prevention, to work in partnership with local communities to create comprehensive evidence-based program packages to prevent youth violence. Key components of a comprehensive evidence-based approach are defined and examples are provided from a variety of community settings (rural and urban) across the nation that illustrate attempts to respond to the unique needs of the communities while maintaining a focus on evidence-based programming and practices. At each YVPC site, the process of selecting prevention and intervention programs addressed the following factors: (1) community capacity, (2) researcher and community roles in selecting programs, (3) use of data in decision-making related to program selection, and (4) reach, resources, and dosage. We describe systemic barriers to these efforts, lessons learned, and opportunities for policy and practice. Although adopting an evidence-based comprehensive approach requires significant upfront resources and investment, it offers great potential for preventing youth violence and promoting the successful development of children, families and communities

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

Background The Ebola epidemics in west Africa and the Democratic Republic of the Congo highlight an urgent need for safe and effective vaccines to prevent Ebola virus disease. We aimed to assess the safety and long-term immunogenicity of a two-dose heterologous vaccine regimen, comprising the adenovirus type 26 vector-based vaccine encoding the Ebola virus glycoprotein (Ad26.ZEBOV) and the modified vaccinia Ankara vector-based vaccine, encoding glycoproteins from Ebola virus, Sudan virus, and Marburg virus, and the nucleoprotein from the Tai Forest virus (MVA-BN-Filo), in Sierra Leone, a country previously affected by Ebola. Methods The trial comprised two stages: an open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2. The study was done at three clinics in Kambia district, Sierra Leone. In stage 1, healthy adults (aged ≥18 years) residing in or near Kambia district, received an intramuscular injection of Ad26.ZEBOV (5×1010 viral particles) on day 1 (first dose) followed by an intramuscular injection of MVA-BN-Filo (1×108 infectious units) on day 57 (second dose). An Ad26.ZEBOV booster vaccination was offered at 2 years after the first dose to stage 1 participants. The eligibility criteria for adult participants in stage 2 were consistent with stage 1 eligibility criteria. Stage 2 participants were randomly assigned (3:1), by computer-generated block randomisation (block size of eight) via an interactive web-response system, to receive either the Ebola vaccine regimen (Ad26.ZEBOV followed by MVA-BN-Filo) or an intramuscular injection of a single dose of meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (MenACWY; first dose) followed by placebo on day 57 (second dose; control group). Study team personnel, except those with primary responsibility for study vaccine preparation, and participants were masked to study vaccine allocation. The primary outcome was the safety of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen, which was assessed in all participants who had received at least one dose of study vaccine. Safety was assessed as solicited local and systemic adverse events occurring in the first 7 days after each vaccination, unsolicited adverse events occurring in the first 28 days after each vaccination, and serious adverse events or immediate reportable events occurring up to each participant’s last study visit. Secondary outcomes were to assess Ebola virus glycoprotein-specific binding antibody responses at 21 days after the second vaccine in a per-protocol set of participants (ie, those who had received both vaccinations within the protocol-defined time window, had at least one evaluable post-vaccination sample, and had no major protocol deviations that could have influenced the immune response) and to assess the safety and tolerability of the Ad26.ZEBOV booster vaccination in stage 1 participants who had received the booster dose. This study is registered at ClinicalTrials.gov, NCT02509494. Findings Between Sept 30, 2015, and Oct 19, 2016, 443 participants (43 in stage 1 and 400 in stage 2) were enrolled; 341 participants assigned to receive the Ad26.ZEBOV and MVA-BN-Filo regimen and 102 participants assigned to receive the MenACWY and placebo regimen received at least one dose of study vaccine. Both regimens were well tolerated with no safety concerns. In stage 1, solicited local adverse events (mostly mild or moderate injection-site pain) were reported in 12 (28%) of 43 participants after Ad26.ZEBOV vaccination and in six (14%) participants after MVA-BN-Filo vaccination. In stage 2, solicited local adverse events were reported in 51 (17%) of 298 participants after Ad26.ZEBOV vaccination, in 58 (24%) of 246 after MVA-BN-Filo vaccination, in 17 (17%) of 102 after MenACWY vaccination, and in eight (9%) of 86 after placebo injection. In stage 1, solicited systemic adverse events were reported in 18 (42%) of 43 participants after Ad26.ZEBOV vaccination and in 17 (40%) after MVA-BN-Filo vaccination. In stage 2, solicited systemic adverse events were reported in 161 (54%) of 298 participants after Ad26.ZEBOV vaccination, in 107 (43%) of 246 after MVA-BN-Filo vaccination, in 51 (50%) of 102 after MenACWY vaccination, and in 39 (45%) of 86 after placebo injection. Solicited systemic adverse events in both stage 1 and 2 participants included mostly mild or moderate headache, myalgia, fatigue, and arthralgia. The most frequent unsolicited adverse event after the first dose was headache in stage 1 and malaria in stage 2. Malaria was the most frequent unsolicited adverse event after the second dose in both stage 1 and 2. No serious adverse event was considered related to the study vaccine, and no immediate reportable events were observed. In stage 1, the safety profile after the booster vaccination was not notably different to that observed after the first dose. Vaccine-induced humoral immune responses were observed in 41 (98%) of 42 stage 1 participants (geometric mean binding antibody concentration 4784 ELISA units [EU]/mL [95% CI 3736–6125]) and in 176 (98%) of 179 stage 2 participants (3810 EU/mL [3312–4383]) at 21 days after the second vaccination. Interpretation The Ad26.ZEBOV and MVA-BN-Filo vaccine regimen was well tolerated and immunogenic, with persistent humoral immune responses. These data support the use of this vaccine regimen for Ebola virus disease prophylaxis in adults